Company intelligence / Profile preview

NewMoo

Ownership: Private
Development stage: Preclinical

Overview

NewMoo has developed a proprietary plant molecular farming platform to express multiple casein proteins in soybeans. Their liquid casein base mimics the functional and sensory properties of animal-derived dairy proteins and can be used by cheese manufacturers without changing existing processes. The company claims its process offers significant sustainability benefits over traditional dairy production. No clinical results as this pertains to food ingredients rather than therapeutics.

Modalities: Recombinant proteinPlant molecular farming (expression of animal proteins in plants)
Industry: Non-Drug Biotech

Partnerships

None publicly disclosed as of June 2025; company mentions working with partners in the dairy industry

Beyond the preview

Go deeper on NewMoo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NewMoo.

Explore the full profile